Trial · NCT04522297
Nor-epinephrine Versus Midodrine/Octreotide in Patients With Hepatorenal Syndrome
NCT04522297, Not applicable, Completed, National Hepatology & Tropical Medicine Research Institute
3 sourcestrials-2026-11-12-0.5.0
Cite this record
ConductScience Library. Nor-epinephrine Versus Midodrine/Octreotide in Patients With Hepatorenal Syndrome. Trials, record NCT04522297. Release trials-2026-11-12-0.5.0, 12 Nov 2026. https://conductscience.org/library/trials/NCT04522297
On this page
Trial
As registered on ClinicalTrials.gov, in the graph's capture of the registry.
- Title
- Nor-epinephrine Versus Midodrine/Octreotide in Patients With Hepatorenal Syndrome
- NCT number
- NCT04522297
- Status
- Completed
- Phases
- Not applicable
- Enrollment
- 91 participants, actual
- Lead sponsor
- National Hepatology & Tropical Medicine Research Institute
- Conditions
- Hepato-Renal Syndrome
- Interventions
- Midodrine/Octreotide, Nor-epinephrine
- First posted
- 2020-08-21
- Last updated
- 2020-08-21
Source ClinicalTrials.gov
Registered outcomes3
Each outcome the trial registered, primary first, in ClinicalTrials.gov's words.
| List | Outcome | Time frame | Description |
|---|---|---|---|
| Primary | Full response | 10 days | the proportion of patients achieved full response defined as return of serum creatinine to a value within 0.3 mg/dl of the baseline value |
| Secondary | Partial response | 10 days | defined as a regression of at least one acute kidney injury stage with a fall in the serum creatinine value to ≥0.3 mg/dl above the baseline serum creatinine value |
| Secondary | Reversal | 10 days | Incidence of HRS reversal defined as at least one serum creatinine value of ≤ 1.5 mg/dl while on treatment. |
Source ClinicalTrials.gov
Outcomes0
Each outcome the trial posted results for, in ClinicalTrials.gov's words.
None in this release.
Results by group0
Each measurement the trial posted, group by group, in the words and numbers it posted.
None in this release.
Participant flow0
How many started, completed or left each group, period by period.
None in this release.
Adverse events0
Each adverse event the trial posted, group by group: the participants affected out of those at risk.
None in this release.
Adverse event totals0
The totals the trial posted for each group.
None in this release.
Papers0
The papers the trial lists on ClinicalTrials.gov.
None in this release.
Grants0
The grants NIH RePORTER links to the trial, newest funded first: NIH's, and some of AHRQ's, CDC's, FDA's and VA's. Each shows its title, principal investigators, organization and funder in its newest year.
None in this release.
Trial comparisons0
Comparisons of the trial's two groups, calculated by ConductScience from the counts it posted.
None in this release.
Tests0
The ConductCognition tests this trial's registered outcomes name, as ScienceGraph matched them in trial-tests-2026-11-12-0.2.1.
None in this release.
Data dates
The day each source was copied for this release.
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this trial from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/trials/v1/NCT04522297
GET https://conductscience.org/api/trials/v1/NCT04522297/registered